Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veeva SystemsMEX:VEEV 94 3-Year RORE % is 16.93 as of Apr. 2026. GuruFocus rates MEX:VEEV with a GF Score™ of 94/100 and a GF Value™ of MXN5,170.92 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 604 Healthcare Providers & Services companies, Veeva Systems ranks better than 66.39% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Veeva Systems's 3-Year RORE % for the quarter that ended in Apr. 2026 was 16.93%.
The industry rank for Veeva Systems's 3-Year RORE % or its related term are showing as below:
MEX:VEEV's 3-Year RORE % is ranked better than 66.39% of 604
companies
in the Healthcare Providers & Services industry
Industry Median: 0.195
vs MEX:VEEV: 16.93
Veeva Systems (MEX:VEEV) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Veeva Systems 3-Year RORE % Related Terms
Veeva Systems 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Veeva Systems's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VEEV vs BTSG, TEM, HQY: 3-Year RORE % Comparison
For the Health Information Services subindustry, Veeva Systems's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veeva Systems 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veeva Systems's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Veeva Systems's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Apr. 2026 and 3-year before.
Veeva Systems (MEX:VEEV) has a 3-Year RORE % of 16.93 as of Apr. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Veeva Systems and its competitors. According to the industry distribution chart, Veeva Systems ranks #203 out of 604 companies in the Healthcare Providers & Services industry, placing it in the top 33.6%.
Is Veeva Systems' 3-Year RORE % too high?
Veeva Systems' current 3-Year RORE % is 16.93. The Healthcare Providers & Services industry median 3-Year RORE % is 0.20. Veeva Systems' value of 16.93 is 8582.1% above this industry median. Based on the distribution chart, Veeva Systems ranks #203 out of 604 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Veeva Systems has a GF Score™ of 94/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Veeva Systems' 3-Year RORE % compare to BTSG and TEM?
According to the Healthcare Providers & Services industry distribution chart, Veeva Systems ranks #203 out of 604 companies for 3-Year RORE %. This puts Veeva Systems in the upper half of its industry. The industry median 3-Year RORE % is 0.20. Veeva Systems' value of 16.93 is 8582.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.20, based on 604 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veeva Systems's current 3-Year RORE % of 16.93 is 8582.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Veeva Systems and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veeva Systems's current 3-Year RORE % is 16.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veeva Systems stock overvalued right now?
Based on GuruFocus' analysis, Veeva Systems (MEX:VEEV) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN5,170.92, compared to a current price of MXN3,460.00 — trading 33.1% below its estimated fair value. The current 3-Year RORE % is 16.93 and 8582.1% above the Healthcare Providers & Services industry median of 0.20. Veeva Systems' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Veeva Systems (MEX:VEEV), the current 3-Year RORE % is 16.93 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veeva Systems (MEX:VEEV) Overvalued in 2026?
Based on GuruFocus' analysis, Veeva Systems stock appears to be undervalued.
The current stock price of MXN3,460.00 is trading 33.1% below its estimated GF Value™ of MXN5,170.92.
GuruFocus considers Veeva Systems to be Significantly Undervalued.
Key valuation signals for MEX:VEEV:
3-Year RORE %: 16.93
GF Value™: MXN5,170.92 vs. price of MXN3,460.00 (33.1% below fair value)
Industry Position: 8582.1% above the Healthcare Providers & Services median (#203 of 604)
No single metric tells the full story. See the MEX:VEEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
94GF Score
Get the complete analysis for MEX:VEEV
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VEEV has been successfully added to your 
